Integer (ITGR) is facing macroeconomic uncertainty related to tariffs, Oppenheimer said in a note Friday as it lowered its rating on the stock.
"We are adopting a wait and see stance," Oppenheimer said.
The firm said it is "fundamentally constructive" on Integer because of the company's exposure to high-growth MedTech segments.
"Our downgrade is a reflection of the stock being at our price target, and the uncertainty around possible tariff-induced structural dislocations," Oppenheimer said.
Oppenheimer downgraded its rating on Integer stock to perform from outperform, and removed its $138 price target.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.